Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied. Voriconazole is metabolised by CYPs 2C19, 2C9 and 3A4 and is an inhibitor of CYP3A4 and P-gp. Voriconazole is unlikely to affect emtricitabine concentrations, but could potentially increase the absorption of tenofovir-DF (inhibition of P-gp), thereby increasing the systemic concentration of tenofovir. No dose adjustment is required, but monitoring of tenofovir-associated adverse reactions, including frequent renal monitoring, is recommended.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking